Pharma CEO: Don't halt AI research, our work is too important

Recursion Pharmaceuticals

How is society supposed to address the risks of artificial intelligence? There are those who argue the conceivable benefits outweigh the immediate danger, and so, restrictions should be pursued lightly.

"I think these broad, blanket suggestions that we stop work [on AI] are a little bit misguided," said Chris Gibson, co-founder and CEO of Recursion Pharmaceuticals, in a recent interview with ZDNET. 

AI in 2023: A year of breakthroughs that left no human thing unchanged These are the jobs most likely to be taken over by AI AI at the edge: 5G and the Internet of Things see fast times ahead Almost half of tech executives say their organizations aren't ready for AI or other advanced initiatives AI in 2023: A year of breakthroughs that left no human thing unchanged

These are the jobs most likely to be taken over by AI

AI at the edge: 5G and the Internet of Things see fast times ahead

Almost half of tech executives say their organizations aren't ready for AI or other advanced initiatives

Editorial standards Show Comments